Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma

Blood

Volumn 130, Issue 22, 2017, Pages 2420-2430

  Carey, Christopher D ^a,b   Gusenleitner, Daniel ^c   Lipschitz, Mikel ^c   Roemer, Margaretha G M ^c,d   Stack, Edward C ^e   Gjini, Evisa ^c   Hu, Xihao ^c   Redd, Robert ^c   Freeman, Gordon J ^c   Neuberg, Donna ^c   Hodi, F Stephen ^c   Liu, Xiaole Shirley ^c   Shipp, Margaret A ^c   Rodig, Scott J ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e PERKINELMER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DIGITAL IMAGING; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REED STERNBERG CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; FLUORESCENT ANTIBODY TECHNIQUE; MACROPHAGE; PATHOLOGY; T LYMPHOCYTE;

B7-H1 ANTIGEN; FLUORESCENT ANTIBODY TECHNIQUE; HODGKIN DISEASE; HUMANS; MACROPHAGES; PROGRAMMED CELL DEATH 1 RECEPTOR; REED-STERNBERG CELLS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 85036496900     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-03-770719     Document Type: Article

References (32)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008.
2. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17): 3268-3277.
3. Roemer MGM, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34(23):2690-2697.
4. Roemer MGM, Advani RH, Redd RA, et al. Classical Hodgkin lymphoma with reduced b2M/MHC class I expression is associated with inferior outcome independent of 9p24.1 status. Cancer Immunol Res. 2016;4(11): 910-916.
5. Reichel J, Chadburn A, Rubinstein PG, et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood. 2015;125(7): 1061-1072.
6. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4): 311-319.
7. Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016; 17(9):1283-1294.
8. Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34(31):3733-3739.
9. Chen R, Zinzani PL, Fanale MA, et al; KEYNOTE-087. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35(19): 2125-2132.
10. Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013; 19(13):3462-3473.
11. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med. 2010;362(10):875-885.
12. Feng Z, Puri S, Moudgil T, et al. Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma. J Immunother Cancer. 2015;3:47.
13. Tóth ZE, Mezey E. Simultaneous visualization of multiple antigens with tyramide signal amplification using antibodies from the same species. J Histochem Cytochem. 2007;55(6): 545-554.
14. Bogusz AM, Baxter RHG, Currie T, et al. Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma. Clin Cancer Res. 2012;18(22):6122-6135.
15. Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2006;30(7):802-810.
16. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486-499.
17. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26(1):677-704.
18. Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5(1):3-8.
19. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99(12): 4283-4297.
20. Thorn M, Guha P, Cunetta M, et al. Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases. Cancer Gene Ther. 2016;23(6): 188-198.
21. Farrar MA, Schreiber RD. The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol. 1993;11(1):571-611.
22. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127): 127ra37.
23. Chevolet I, Speeckaert R, Schreuer M, et al. Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma. OncoImmunology. 2015;4(3):e982382.
24. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013;14(12): 1212-1218.
25. Morris CS, Stuart AE. Reed-Sternberg/ lymphocyte rosette: lymphocyte subpopulations as defined by monoclonal antibodies. J Clin Pathol. 1984;37(7):767-771.
26. Diepstra A, Niens M, Vellenga E, et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin’s lymphoma. Lancet. 2005;365(9478):2216-2224.
27. 1 T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res. 2013; 1(4):235-244.
28. Haabeth OAW, Tveita AA, Fauskanger M, et al. How do CD4(1) T cells detect and eliminate tumor cells that either lack or express MHC class II molecules? Front Immunol. 2014; 5(APR):174.
29. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol. 2010;28(1):445-489.
30. Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3–potential mechanisms of action. Nat Rev Immunol. 2015;15(1):45-56.
31. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene. 2008;27(45): 5932-5943.
32. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011; 29:235-271.